Recently, Shenzhen Baiyin Biotechnology Co., Ltd. completed Series A financing of over RMB 200 million. Investors in this round include Guangzhou Pharmaceutical Capital, L'Oréal, Guangxin Fund, Fuhua Capital, Junlian Capital, Cornerstone Capital, Zhongke Advanced, Woble Union, Starbucks Shenghui, and Junco Danmu. This round of financing will mainly be used for upgrading AI platforms for biomaterials research and development, innovative biomaterials research and development, large-scale production, product development and market expansion.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.